CYTK Q3 2023 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$378,000-85.0% YoY

Gross Profit

-$82M-21733.9% margin

Operating Income

-$122M-32345.2% margin

Net Income

-$129M-34238.6% margin

EPS (Diluted)

$-1.35

QoQ Revenue Growth

-56.4%

Cash Flow

Operating Cash Flow

-$96M

Free Cash Flow

-$96M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$741M

Total Liabilities

$1.2B

Stockholders' Equity

-$439M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$378,000	$3M	-85.0%
Gross Profit	-$82M	-$60M	-36.4%
Operating Income	-$122M	-$108M	-12.7%
Net Income	-$129M	-$142M	+9.1%

Revenue Segments

Research And Development

$378,000100%